Gubra Revenue

Gubra had revenue of 2.49B DKK in the half year ending June 30, 2025, with 2,347.66% growth. This brings the company's revenue in the last twelve months to 2.64B, up 1,078.32% year-over-year. In the year 2024, Gubra had annual revenue of 265.74M with 29.63% growth.

Revenue (ttm)

2.64B

Revenue Growth

+1,078.32%

P/S Ratio

2.99

Revenue / Employee

9.59M

Employees

260

Market Cap

7.88B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	265.74M	60.74M	29.63%
Dec 31, 2023	205.01M	5.62M	2.82%
Dec 31, 2022	199.38M	-55.95M	-21.91%
Dec 31, 2021	255.33M	83.03M	48.19%
Dec 31, 2020	172.30M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Novo Nordisk	315.60B
Coloplast	27.87B
Genmab	24.48B
ALK-Abelló	6.08B
Demant	22.59B
H. Lundbeck	24.08B
Zealand Pharma	9.16B
Ambu A/S	6.04B

Revenue Rankings

Gubra News

6 months ago - Gubra’s Innovation in Peptide-Based Drug Discovery - Nasdaq
9 months ago - Healthy Returns: AbbVie is the newest potential weight loss drug market player - CNBC
9 months ago - AbbVie Steps Into The Ring In The Obesity Drug Wars - Seeking Alpha
9 months ago - AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - Benzinga
9 months ago - AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal - Investopedia
9 months ago - AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal - GuruFocus
9 months ago - AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. - Investor's Business Daily
9 months ago - AbbVie forays into obesity market with up to $2.2B Gubra license deal - Seeking Alpha

More News